Evidence map›Paper›PMID 42719575›Full record

ReviewFrontiers in immunology2026

SARS-CoV-2 ORF8: an accessory protein at the interface of immune evasion and inflammation.

Carolina Schäfer, Cristopher Blamey, Rocío Balbiano, Javier Mena, Claudio Acuña-Castillo, Ana María Sandino

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Carolina SchäferCentro de Biotecnología Acuícola, Facultad de Química y Biología, Universidad de Santiago de Chile, Santiago, Chile.
Cristopher BlameyCentro de Biotecnología Acuícola, Facultad de Química y Biología, Universidad de Santiago de Chile, Santiago, Chile.
Rocío BalbianoCentro de Biotecnología Acuícola, Facultad de Química y Biología, Universidad de Santiago de Chile, Santiago, Chile.
Javier MenaCentro de Biotecnología Acuícola, Facultad de Química y Biología, Universidad de Santiago de Chile, Santiago, Chile.
Claudio Acuña-CastilloCentro de Biotecnología Acuícola, Facultad de Química y Biología, Universidad de Santiago de Chile, Santiago, Chile.
Ana María SandinoCentro de Biotecnología Acuícola, Facultad de Química y Biología, Universidad de Santiago de Chile, Santiago, Chile.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

SARS-CoV-2 ORF8 is a rapidly evolving accessory protein that modulates host immunity through both intracellular and extracellular mechanisms. Intracellularly, ORF8 disrupts antigen presentation by reducing cell-surface MHC-I and is linked to endoplasmic reticulum remodeling and altered stress responses. Extracellularly, secreted ORF8 behaves as a virokine that can amplify inflammatory programs in myeloid and dendritic cells, with potential implications for acute severity and tissue-specific pathology. ORF8 is also reported to antagonize type I interferon induction through effects on IRF3-dependent pathways. Clinically, circulating ORF8 has been associated with disease severity, and persistent detection of ORF8 after viral RNA becomes undetectable has been reported in some individuals with post-acute symptoms. However, whether this persistence reflects a direct pathogenic role or instead marks ongoing viral burden and immune activation remains unresolved. In this review, we summarize recent findings on the pleiotropic effects of ORF8 and outline key priorities to clarify when ORF8 acts primarily as an immune-evasion factor, an inflammatory amplifier, or both. Collectively, the evidence reviewed here identifies ORF8 as a promising candidate for further mechanistic studies, whose biomarker potential and therapeutic relevance warrant rigorous evaluation in acute and post-acute COVID-19.

Indexed as

COVID-19Immune EvasionInflammationSARS-CoV-2Viral ProteinsAnimalsHumansORF8 protein, SARS-CoV-2Viral Proteinsendoplasmic reticulum stressIFN pathwayimmune evasionmajor histocompatibility complex class IORF8SARS-CoV-2virokine

Identifiers

PMID42719575
PMCPMC13555339

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.